Handok 
Welcome,         Profile    Billing    Logout  
 14 Products   88 Diseases  14 Products   14 Trials   565 News 
80 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tenelia (teneligliptin) / Daiichi Sankyo, Mitsubishi Tanabe
TOPLEVEL, NCT02449330: Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction With Type 2 Diabetes Mellitus Study

Recruiting
4
936
Japan
Teneligliptin
National Cerebral and Cardiovascular Center
Diabetes Mellitus, Type 2
06/20
06/23
TERA 304, NCT05504239: Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin

Recruiting
3
228
RoW
Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet, Teneligliptin Placebo Oral Tablet
Handok Inc.
Type 2 Diabetes
11/24
03/25
TERA 305, NCT05504226: Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin

Completed
3
214
RoW
Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet, Teneligliptin Placebo Oral Tablet
Handok Inc.
Type 2 Diabetes
11/23
06/24
ChiCTR-IIC-17011858: An open-label, single- and multiple-dose study to investigate the pharmacokinetics of MP-513 in healthy Chinese volunteers

Recruiting
1
48
 
Subjects will receive 8 doses of 20 mg MP-513. ;Subjects will receive 1 dose of 40 mg MP-513. ;Subjects will receive 1 dose of 80 mg MP-513.
Beijing Shijitan Hospital Capital Medical University; Mitsubishi Tanabe Pharma Corporation, Mitsubishi Tanabe Pharma Corporation
diabetes
 
 
HD-MP-106, NCT06339788: Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

Completed
1
40
RoW
HD-P023, Teneligliptin, Empagliflozin
Handok Inc.
Healthy Volunteers
06/24
06/24
NCT06889350: Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

Recruiting
1
40
RoW
HD-P023, Teneligliptin, Empagliflozin High
Handok Inc.
Healthy Volunteers
04/25
04/25
Soliris (eculizumab) / AstraZeneca
2019-001453-10: A Low-Interventional Study Documenting the Efficacy, Health-Related Quality of Life, and Safety of Standard-Of-Care Treatment with Eculizumab or Treatment with Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Un estudio de baja intervención que documenta la eficacia, la calidad de vida relacionada con la salud y la seguridad del tratamiento se referencia con eculizumab o el tratamiento con ravulizumab en pacientes con hemoglobinuria nocturna paroxística

Ongoing
4
200
Europe
ECULIZUMAB, Ultomiris, Concentrate for solution for infusion, Soliris 300, ULTOMIRIS
Roche Farma S. A. U. que realiza el ensayo en España y que actua como representante F.Hoffmann-La Roche Ltd, F. Hoffman-La Roche Ltd., Chugai Pharmaceutical Co. Ltd
Paroxysmal nocturnal hemoglobinuria (PNH) that is treated with either eculizumab or ravulizumab as per local label Hemoglobinuria paroxística nocturna (HPN) que se trata con eculizumab o ravulizumab según la etiqueta local, PNH is a rare, acquired life-threatening disease, characterized by presence of impaired red blood cells that are easily destroyed, leading to hemoglobin in the urine and anemia as main manifestations HPN es enfermedad rara, adqui q pone en peligro la vida, por la presencia de glóbu rojos deteriorados q se destruyen fácil, lo q lleva a la hemoglobina en orina y anemia como manifestaciones ppales, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2019-001619-21: OPTIMIZATION OF MAINTENANCE DOSE WITH ECULIZUMAB ACCORDING TO WEIGHT IN PATIENTS WITH ATYPIC HAEMOLITHIC URINE MUSCLE SYNDROME OPTIMIZACIÓN DE LA DOSIS DE MANTENIMIENTO CON ECULIZUMAB SEGÚN EL PESO EN PACIENTES CON SÍNDROME HEMOLÍTICO URÉMICO ATÍPICO

Not yet recruiting
4
10
Europe
Solution for infusion, SOLIRIS
HOSPITAL UNIVERSITARI DE BELLVITGE- IDIBELL, HOSPITAL UNIVERSITARI DE BELLVITGE-IDIBELL
ATYPICAL HEMOLYTIC UREMIC SYNDROME SÍNDROME HEMOLÍTICO URÉMICO ATÍPICO, ATYPICAL HEMOLYTIC UREMIC SYNDROME SÍNDROME HEMOLÍTICO URÉMICO ATÍPICO, Not possible to specify
 
 
2019-003440-74: Phase 4, Single-Arm Study of Ravulizumab in Adult Participants with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with High-Dose Eculizumab

Not yet recruiting
4
20
Europe
ULTOMIRIS, ALXN1210, Concentrate for solution for infusion, ULTOMIRIS
Alexion Pharmaceuticals Inc., Alexion Pharmaceuticals, Inc.
Paroxysmal nocturnal hemoglobinuria (PNH), Paroxysmal nocturnal hemoglobinuria (PNH), Diseases [C] - Blood and lymphatic diseases [C15]
 
 
BEST-NMOSD, NCT07010302: Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD

Not yet recruiting
4
160
Europe, US
Rituximab (R), Rituxan, Truxima, Eculizumab (Soliris®), Ravulizumab, Satralizumab, Inebilizumab
Massachusetts General Hospital, Patient-Centered Outcomes Research Institute, Charite University, Berlin, Germany, The Sumaira Foundation
NMOSD
02/29
02/30
NCT02946463 / 2016-002025-11: ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Checkmark In PNH
Apr 2018 - Apr 2018: In PNH
Completed
3
272
Europe, Canada, Japan, US, RoW
Ravulizumab, Eculizumab
Alexion Pharmaceuticals, Inc.
Paroxysmal Nocturnal Hemoglobinuria (PNH)
02/23
02/23
NCT06987864: An Extension Clinical Study of BCD-148 for the Treatment of Patients With PNH Previously Treated in Clinical Study No. BCD-148-2/NOCTURN

Completed
3
24
RoW
eculizumab
Biocad
Paroxysmal Nocturnal Hemoglobinuria (PNH)
11/22
11/22
NCT03748823 / 2017-002370-39: Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Completed
3
139
Europe, Canada, US, RoW
Ravulizumab OBDS, Ravulizumab, ALXN1210
Alexion Pharmaceuticals, Inc.
Paroxysmal Nocturnal Hemoglobinuria
02/21
08/23
2020-003565-19: Espacement personnalisé des perfusions d’eculizumab basé sur un suivi thérapeutique pharmacologique : évaluation médicoéconomique prospective multicentrique chez les patients en rémission atteints d’un syndrome hémolytique et urémique atypique nécessitant un traitement au long cours. Espacement personnalisé des perfusions d’eculizumab basé sur un suivi thérapeutique pharmacologique : évaluation médicoéconomique prospective multicentrique chez les patients en rémission atteints d’un syndrome hémolytique et urémique atypique nécessitant un traitement au long cours.

Not yet recruiting
3
80
Europe
SOLIRIS, L04AA25, Solution for injection, SOLIRIS
CHRU DE TOURS, CHRU DE TOURS
Patients en rémission atteints d’un syndrome hémolytique et urémique atypique nécessitant un traitement au long cours par eculizumab Patients en rémission atteints d’un syndrome hémolytique et urémique atypique nécessitant un traitement au long cours par eculizumab, Patients en rémission atteints d’un syndrome hémolytique et urémique atypique nécessitant un traitement au long cours par eculizumab Patients en rémission atteints d’un syndrome hémolytique et urémique atypique nécessitant un traitement au long cours par eculizumab, Not possible to specify
 
 
ECU-MG-303, NCT03759366 / 2016-001384-37: A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

Completed
3
12
Japan, US
Eculizumab
Alexion Pharmaceuticals, Inc.
Myasthenia Gravis, Myasthenia Gravis, Juvenile Form, Myasthenia Gravis, Generalized
01/22
11/23
ALPHA, NCT04469465 / 2019-003829-18: Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)

Completed
3
86
Europe, Canada, Japan, US, RoW
Danicopan, ALXN2040, Placebo, C5 Inhibitor
Alexion Pharmaceuticals, Inc.
Paroxysmal Nocturnal Hemoglobinuria
06/22
01/24
EspacECU, NCT04859608: Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring

Completed
3
40
Europe
Spacing of Eculizumab infusions
University Hospital, Tours, Centre Hospitalier Universitaire, Amiens, University Hospital, Angers, Centre Hospitalier Universitaire de Besancon, University Hospital, Caen, Centre Hospitalier of Chartres, Nantes University Hospital, University of Nancy, Poitiers University Hospital, Rennes University Hospital, University Hospital, Rouen, University Hospital, Strasbourg, France, Centre Hospitalier Universitaire de Nice, Hôpital Necker-Enfants Malades, Tenon Hospital, Paris, University Hospital, Lille, Reims University hospital, University Hospital, Clermont-Ferrand, Assistance Publique Hopitaux De Marseille, Hospices Civils de Lyon
Hemolytic-Uremic Syndrome, Atypical
06/22
12/23
APPLY-PNH, NCT04558918 / 2019-004665-40: Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

Hourglass Jun 2025 - Jun 2025 : 2-yrs safety and efficacy data for PNH
Completed
3
97
Europe, Japan, US, RoW
LNP023, iptacopan, Eculizumab, Ravulizumab
Novartis Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria (PNH)
09/22
03/23
COMMODORE 2, NCT04434092 / 2019-004931-21: A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors

Active, not recruiting
3
204
Europe, Japan, RoW
Crovalimab, Eculizumab
Hoffmann-La Roche, Chugai Pharmaceutical
Paroxysmal Nocturnal Hemoglobinuria
11/22
09/27

Ongoing
3
66
Europe
ECULIZUMAB, Concentrate for solution for infusion, Soliris 300 mg solution à diluer pour perfusion
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (AP-HP), DGOS
Adult patients with aHUS associated with HE and severe kidney involvement (needing dialysis or serum creatinine ≥ 354µM)., ND, Diseases [C] - Cardiovascular Diseases [C14]
 
 
ACCESS 2, NCT05131204 / 2020-002761-33: Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

Terminated
3
3
US
Cemdisiran, ALN-CC5, Eculizumab, Soliris, Pozelimab, REGN3918, Ravulizumab, ALXN1210, Ultomiris
Regeneron Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria
07/23
07/23
ConfIdeS, NCT04935177: Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx

Active, not recruiting
3
64
US
Imlifidase, IdeS, HMED-IdeS, PLEX, Plasma exchange, PE, IVIg, Intravenous immunoglobulin, Anti-CD20 antibodies, Rituximab, Eculizumab, Soliris, Remain on wait list
Hansa Biopharma AB
Kidney Transplantation in Highly Sensitized Patients
06/25
06/25
NCT06932744: Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

Recruiting
3
66
RoW
MY008211A tablets, Eculizumab Injection
Wuhan Createrna Science and Technology Co., Ltd
Paroxysmal Nocturnal Haemoglobinuria (PNH)
12/25
12/25
HRS-5965-301, NCT06593938: A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

Active, not recruiting
3
76
RoW
HRS-5965 capsule, Eculizumab Injection
Chengdu Suncadia Medicine Co., Ltd.
Paroxysmal Nocturnal Hemoglobinuria
12/25
12/25
ECU-MG-304, NCT06764160: Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG

Active, not recruiting
3
15
RoW
Eculizumab
Alexion Pharmaceuticals, Inc.
Generalized Myasthenia Gravis (gMG), Refractory gMG
01/26
01/26
ECU-NMO-304, NCT06724809: Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD

Recruiting
3
21
RoW
eculizumab
Alexion Pharmaceuticals, Inc., AstraZeneca
NMOSD, Neuromyelitis Optica Spectrum Disorders
04/27
04/27
HSK39297-301, NCT06799546: A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy

Recruiting
3
66
RoW
HSK39297 tablets, Eculizumab Injection
Haisco Pharmaceutical Group Co., Ltd.
PNH
12/25
12/25
Soliris, NCT05886244: Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China

Completed
3
25
RoW
Eculizumab
Alexion Pharmaceuticals, Inc., AstraZeneca
Paroxysmal Nocturnal Hemoglobinuria
04/25
04/25
GEMECULI, NCT05702996: Multicenter, Uncontrolled Pilot Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies

Not yet recruiting
3
10
Europe
Eculizumab administration
University Hospital, Rouen
Thrombotic Microangiopathies
09/25
09/25
NCT06449001: Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

Recruiting
3
6
Europe
Danicopan
Alexion Pharmaceuticals, Inc.
Paroxysmal Nocturnal Hemoglobinuria, PNH, Extravascular Hemolysis
07/27
07/28
Soliris, NCT05876351: Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China

Completed
3
25
RoW
Eculizumab
Alexion Pharmaceuticals, Inc., AstraZeneca
Atypical Hemolytic Uremic
05/25
05/25
HYPERSHU, NCT05726916: Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome

Recruiting
3
66
Europe
Soliris®, Eculizumab, Renin angiotensin system blockers
Assistance Publique - Hôpitaux de Paris
Hypertensive Emergency-associated Hemolytic Uremic Syndrome
05/26
11/27
ACCESS-1, NCT05133531 / 2020-004486-40: A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment

Recruiting
3
190
Europe, Canada, Japan, US, RoW
Ravulizumab, ALXN1210, Ultomiris, Pozelimab, REGN3918, Cemdisiran, ALN-CC5, Eculizumab, Soliris
Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Inc.
Paroxysmal Nocturnal Hemoglobinuria
01/27
01/27
COMMODORE 1, NCT04432584 / 2020-000597-26: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors

Active, not recruiting
3
190
Europe, Canada, Japan, US, RoW
Crovalimab, Eculizumab
Hoffmann-La Roche, Chugai Pharmaceutical
Paroxysmal Nocturnal Hemoglobinuria
09/27
09/27
2019-001829-26: A Trial to Evaluate the Safety and Activity of Eculizumab in PediatricPatients with Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD) Ensayo para evaluar la seguridad y actividad de eculizumab en pacientes pediátricos con trastorno del espectro de la neuromielitis óptica recidivante

Not yet recruiting
2/3
15
Europe
Soliris, Soliris, Concentrate for solution for infusion, Soliris
Alexion Pharmaceuticals Inc., ALEXION PHARMACEUTICALS INCORPORATED, Alexion Pharmaceuticals Inc, Alexion Pharmaceuticals Inc.
Neuromyelitis Optica Spectrum Disorder (NMOSD) Trastorno del espectro de la neuromielitis óptica (TENMO), Neuromyelitis Optica Spectrum Disorder (NMOSD) Trastorno del espectro de la neuromielitis óptica (TENMO), Diseases [C] - Nervous System Diseases [C10]
 
 
ECU-NMO-303, NCT04155424 / 2019-001829-26: A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

Terminated
2/3
5
Europe, Canada, Japan, US, RoW
Eculizumab, Soliris
Alexion Pharmaceuticals, Inc., Alexion Pharmaceuticals Inc, Alexion Pharmaceuticals Inc.
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
07/23
07/23
ACTRN12611000880943: Safety & Efficacy of Eculizumab to Prevent antibody mediated rejection in Living Donor Kidney Transplant Recipients Requiring Desensitization

Recruiting
2
80
 
Alexion Pharmaceuticals Australasia Pty Ltd, Alexion Pharmaceuticals Australasia Pty Ltd
Kidney transplant
 
 
ACTRN12611000461998: Study to evaluate if eculizumab is efficient and safe enough to be used for treatment of children with atypical hemolytic-uremic syndrome

Active, not recruiting
2
15
 
Alexion Pharmaceuticals Australasia Pty Ltd, Alexion Pharmaceuticals Australasia Pty Ltd
Atypical Hemolytic-Uremic Syndrome
 
 
ACTRN12612000333819: Safety and Efficacy of Eculizumab to prevent antibody mediated rejection in sensitized kidney transplant recipients from a deceased donor

Recruiting
2
40
 
Alexion Pharmaceuticals Inc, Alexion Pharmaceuticals Inc
kidney transplant
 
 
2017-003916-37: Stopping Eculizumab Treatment Safely in atypical Haemolytic Uraemic Syndrome (SETS aHUS)

Not yet recruiting
2
50
Europe
Solaris, Infusion, Solaris
Newcastle Upon Tyne Hospitals NHS Foundation Trust, National Institute for Health Research
Atypical Haemolytic Uraemic Syndrome (aHUS), aHUS is a rare disease caused by a fault in the complement system. The complement system is part of your body’s immune response that attacks bugs., Diseases [C] - Immune System Diseases [C20]
 
 
2017-004307-51: Inflammation inhibitors to reduce brain injury after a hemorrhagic stroke. Ontstekingsremmers om schade na bloeding tussen hersenvliezen te verminderen.

Ongoing
2
40
Europe
Powder for infusion, Soliris
University Medical Center Utrecht, ZonMW/Hersenstichting, Alexion Pharmaceuticals
Aneurysmal subarachnoid hemorrhage Aneurysmatische subarachnoïdale bloeding, Stroke Hersenvliesbloeding, Diseases [C] - Cardiovascular Diseases [C14]
 
 
2018-004382-13: Safety and efficacy of Cemdisiran in athypical hemolytic uremic syndrome Sicurezza ed efficacia di Cendisiran nella Sindrome emolitico-uremica atipica.

Not yet recruiting
2
12
Europe
ALN-CC5, [ALN-62643], Solution for injection
IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI, Alnylam Pharmaceutical Inc. Cambridge, MA, Istituto di Ricerche Farmacologiche Mario negri
Atypical Hemolytic Uremic Syndrome Sindrome emolitico uremica atipica, Atypical Hemolytic Uremic Syndrome Sindrome emolitico uremica atipica, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2020-003168-22: Study evaluating the efficacy of eculizumab in the treatment of gemcitabine-induced thrombotic microangiopathies. Etude évaluant l’efficacité de l’eculizumab dans le traitement des microangiopathies thrombotiques induites par la gemcitabine

Not yet recruiting
2
10
Europe
SOLIRIS®, EU/1/07/393/001, Solution for infusion, SOLIRIS®
Rouen University Hospital, Rouen University Hospital
Thrombotic microangiopathies induced by gemcitabine Microangiopathies thrombotiques induites par la gemcitabine, Thrombotic microangiopathies induced by gemcitabine Microangiopathies thrombotiques induites par la gemcitabine, Diseases [C] - Cancer [C04]
 
 
NCT04888507: Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy

Completed
2
6
Europe
Pozelimab, REGN3918, Cemdisiran, ALN-CC5
Regeneron Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria
05/22
05/23
REDEEM-1, NCT05116774 / 2020-004438-39: BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy

Terminated
2
12
Europe
Eculizumab, Soliris, Ravulizumab, Ultomiris, ALXN1210, ravulizumab-cwvz, BCX9930
BioCryst Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria (PNH)
09/23
09/23
NCT06513338: Complement C5 mAb in the Treatment of Anti-GBM Disease

Completed
2
8
RoW
Eculizumab
Peking University First Hospital
Autoimmune Diseases
12/24
12/24
NCT04702568 / 2020-000501-93: A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Terminated
2
19
Europe, RoW
BCX9930, Eculizumab, Ravulizumab
BioCryst Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria, PNH
10/23
10/23
EASE-NMO, NCT06673394: Eculizumab for Acute Attack of Neuromyelitis Optica Spectrum Disorder

Not yet recruiting
2
75
NA
Complement protein C5 inhibitor, eculizumab, IVMP, methylprednisolone, prednisolone
Tianjin Medical University General Hospital
Neuromyelitis Optica Spectrum Disorder Attack
12/25
12/25
ChiCTR2400084781: A Study on the Efficacy and Safety of Sequential Efgartigimod and Telitacicept Therapy in the Treatment of Generalized Myasthenia Gravis

Not yet recruiting
2
30
 
The patients in the treatment group received a dose of 10mg/kg of eculizumab via intravenous infusion over 1 hour once a week for 4 consecutive weeks in the first month. Starting from the second month, they began receiving a subcutaneous injection of 240mg of Telitacicept acetate weekly, and continued long-term Telitacicept acetate treatment until the end of the 24-week study observation period.
Peking University People's Hospital; Peking University People's Hospital, The research was funded by the National Natural Science Foundation of China (Grant No. 81303013).
myasthenia gravis
 
 
NCT05646563: Study of NM8074 in Adult PNH Patients with Inadequate Response to Soliris

Not yet recruiting
2
12
NA
NM8074, Soliris, Eculizumab
NovelMed Therapeutics
Paroxysmal Nocturnal Hemoglobinuria
05/27
01/28
NCT05731050: Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Not yet recruiting
2
6
NA
NM8074
NovelMed Therapeutics
PNH - Paroxysmal Nocturnal Hemoglobinuria
09/27
03/28
NCT06453135: Eculizumab for Prevention of Antibody-Mediated Rejection in ABO-Incompatible Living Donor Kidney Transplantation

Not yet recruiting
1/2
30
RoW
Eculizumab, Soliris
Tao Lin
Kidney Transplantation
07/25
12/25
NCT04103489: The Use of Eculizumab in HELLP Syndrome

Completed
1
3
US
Eculizumab, Soliris
Johns Hopkins University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
HELLP Syndrome (HELLP), Third Trimester, Complement Abnormality, Morbidity;Newborn, Maternal Injury, Preeclampsia Severe
08/23
09/23
NCT05863442: Comparative PK, Safety, Tolerability, Immunogenicity, and PD Profile Study of TUR03 and Soliris in Healthy Participants

Recruiting
1
120
RoW
Soliris 300 MG in 30 ML Injection, TUR03 300 MG in 30 ML Injection
Turgut Ardika PTY LTD
Healthy
07/24
10/24
SOLID-C19, NCT04288713: Eculizumab (Soliris) in Covid-19 Infected Patients

Available
N/A
NA
Eculizumab
Hudson Medical
Coronavirus
 
 
NCT04355494: SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19

No Longer Available
N/A
Europe, US
eculizumab, Soliris
Alexion Pharmaceuticals
COVID-19, Pneumonia, Viral, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
 
 
NCT04802083: COVID-19 Soliris Expanded Access Protocol

No Longer Available
N/A
NA
Eculizumab, Soliris, monoclonal antibody
Alexion Pharmaceuticals
Covid19
 
 
NAP, NCT04671810: Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria®

Completed
N/A
44
RoW
Elizaria®, Eculizumab
AO GENERIUM
Paroxysmal Nocturnal Hemoglobinuria
12/22
05/23
NCT05982938: Danicopan Early Access Program

Available
N/A
NA
Danicopan, ALXN2040
Alexion Pharmaceuticals, Inc.
Paroxysmal Nocturnal Hemoglobinuria, PNH, Extravascular Hemolysis
 
 
NCT06888622: BLAZE-Limiting Approach in NMOSD

Completed
N/A
9
RoW
Eculizumab administration
Huashan Hospital
Neuromyelitis Optica Spectrum Disorders (NMOSD)
03/25
03/25
SolirisPMS, NCT06448715: Real-World Treatment Study of Soliris (Eculizumab)

Completed
N/A
11
RoW
AstraZeneca
Observational
01/25
01/25
m-TMA, NCT06098378: Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With Eculizumab

Recruiting
N/A
30
Europe
University Hospital, Strasbourg, France
Thrombotic Microangiopathies
06/25
06/25
ChiCTR2300067949: The real world study of Eculizumab for paroxysmal nocturnal hemoglobinuria treatment in China

Not yet recruiting
N/A
10
 
Eculizumab
West China Hospitai, Sichuan University; West China Hospitai, Sichuan University, Apply for hospital project funds
paroxysmal nocturnal hemoglobinuria
 
 
ChiCTR2500098555: Study on the Safety and Efficacy of Eculizumab in Different Subgroups of Adults with Refractory Myasthenia Gravis

Recruiting
N/A
60
 
None; None
Shijiazhuang People s Hospital; Shijiazhuang People s Hospita, Hebei Provincial Myasthenia Gravis Center and key laboratory of Myasthenia gravis research.
Myasthenia gravis
 
 
eftansomatropin alfa (GX-H9) / Genexine
NCT04633057: A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency

Completed
3
168
RoW
TJ101, NordiFlex
TJ Biopharma Co., Ltd.
Pediatric Growth Hormone Deficiency
07/23
07/23
ersodetug (RZ358) / Rezolute
sunRIZE, NCT06208215: RZ358 Treatment for Congenital Hyperinsulinism

Recruiting
3
56
Europe, Canada, US, RoW
RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC, RZ358 (10 mg/kg) or Placebo + SOC, RZ358 (5-10 mg/kg) + SOC
Rezolute
Congenital Hyperinsulinism
04/25
09/26
NCT06881992: A Phase 3 Study of Ersodetug in Patients With Tumor-Associated Hyperinsulinism

Recruiting
3
48
US
Ersodetug, Placebo
Rezolute
Tumor- Associated Hyperinsulinism
09/27
09/27
RZ402 / Rezolute
NCT05712720: Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)

Active, not recruiting
2
100
US
Experimental: Group 1 - 50mg RZ402, Experimental: Group 2 - 200mg RZ402, Experimental: Group 3 - 400mg RZ402, Placebo: Group 4 - Placebo
Rezolute
Diabetic Macular Edema
05/24
05/25
tovecimig (CTX-009) / ABL Bio, Compass Therap
COMPANION-002, NCT05506943: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers

Active, not recruiting
2/3
150
US
CTX-009, Paclitaxel
Compass Therapeutics
Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
07/25
12/25
COMPANION-003, NCT05513742: A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer

Completed
2
49
US
CTX-009
Compass Therapeutics
Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
04/25
05/25
NCT04492033: A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients

Terminated
1/2
41
RoW
CTX-009 (ABL001), Paclitaxel, Irinotecan
Handok Inc., Compass Therapeutics, ABL Bio, Inc.
P1b: Advanced Solid Tumors, P2: Biliary Tract Cancer
01/24
01/25
NCT06548412: CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

Recruiting
1/2
50
US
Gemcitabine, Cisplatin, Durvalumab, CTX-009
M.D. Anderson Cancer Center, Compass Therapeutics, Inc
Metastatic Biliary Tract Cancer
05/27
05/29
NCT05167448: A Study of ES104 in Patients With Metastatic Colorectal Cancer

Active, not recruiting
1/2
58
RoW
ES104
Elpiscience (Suzhou) Biopharma, Ltd.
Metastatic Colorectal Cancer
05/26
07/26
ragistomig (ABL503) / ABL Bio, I-Mab
ABL503-1001, NCT04762641: This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors

Recruiting
1
100
US, RoW
ABL503
ABL Bio, Inc.
Advanced Solid Tumor
11/25
06/26
ABL501 / ABL Bio
NCT05101109: Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

Completed
1
24
RoW
ABL501, Bispecific antibody for LAG-3 and PD-L1
ABL Bio, Inc.
Advanced Solid Tumor
05/24
05/24
ABL103 / ABL Bio
ABL103-1001, NCT06126666: A Study with ABL103 in Subjects with Advanced or Metastatic Solid Tumors

Recruiting
1
96
RoW
ABL103
ABL Bio, Inc.
Advanced Solid Tumor
06/25
11/27
SBP-101 / SPARK BioPharma
NCT06747923: SB17170 Phase 2 Trial in IPF Patients

Recruiting
2
30
RoW
SB17170, Placebo
SPARK Biopharma
IPF, Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
04/26
10/26
NCT05795192: SB17170 Phase1 Trial in Healthy Volunteer

Completed
1
64
RoW
SB17170, Placebo
SPARK Biopharma
Safety Issues, Tolerability, Pharmacokinetics, Pharmacodynamics
02/24
03/24
NCT05522868: SB17170 Phase 1 Clinical Trial in Solid Tumors

Active, not recruiting
1
50
RoW
SB17170
SPARK Biopharma
Solid Tumor
05/25
06/25
NCT06846684: A Open-label, Drug-Drug Interaction With SB_MDZ in Healty Adult Subjects

Active, not recruiting
1
12
RoW
SB17170, SB_MDZ
SPARK Biopharma
Drug Drug Interaction (DDI)
06/25
06/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tenelia (teneligliptin) / Daiichi Sankyo, Mitsubishi Tanabe
TOPLEVEL, NCT02449330: Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction With Type 2 Diabetes Mellitus Study

Recruiting
4
936
Japan
Teneligliptin
National Cerebral and Cardiovascular Center
Diabetes Mellitus, Type 2
06/20
06/23
TERA 304, NCT05504239: Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin

Recruiting
3
228
RoW
Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet, Teneligliptin Placebo Oral Tablet
Handok Inc.
Type 2 Diabetes
11/24
03/25
TERA 305, NCT05504226: Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin

Completed
3
214
RoW
Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet, Teneligliptin Placebo Oral Tablet
Handok Inc.
Type 2 Diabetes
11/23
06/24
ChiCTR-IIC-17011858: An open-label, single- and multiple-dose study to investigate the pharmacokinetics of MP-513 in healthy Chinese volunteers

Recruiting
1
48
 
Subjects will receive 8 doses of 20 mg MP-513. ;Subjects will receive 1 dose of 40 mg MP-513. ;Subjects will receive 1 dose of 80 mg MP-513.
Beijing Shijitan Hospital Capital Medical University; Mitsubishi Tanabe Pharma Corporation, Mitsubishi Tanabe Pharma Corporation
diabetes
 
 
HD-MP-106, NCT06339788: Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

Completed
1
40
RoW
HD-P023, Teneligliptin, Empagliflozin
Handok Inc.
Healthy Volunteers
06/24
06/24
NCT06889350: Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

Recruiting
1
40
RoW
HD-P023, Teneligliptin, Empagliflozin High
Handok Inc.
Healthy Volunteers
04/25
04/25
Soliris (eculizumab) / AstraZeneca
2019-001453-10: A Low-Interventional Study Documenting the Efficacy, Health-Related Quality of Life, and Safety of Standard-Of-Care Treatment with Eculizumab or Treatment with Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Un estudio de baja intervención que documenta la eficacia, la calidad de vida relacionada con la salud y la seguridad del tratamiento se referencia con eculizumab o el tratamiento con ravulizumab en pacientes con hemoglobinuria nocturna paroxística

Ongoing
4
200
Europe
ECULIZUMAB, Ultomiris, Concentrate for solution for infusion, Soliris 300, ULTOMIRIS
Roche Farma S. A. U. que realiza el ensayo en España y que actua como representante F.Hoffmann-La Roche Ltd, F. Hoffman-La Roche Ltd., Chugai Pharmaceutical Co. Ltd
Paroxysmal nocturnal hemoglobinuria (PNH) that is treated with either eculizumab or ravulizumab as per local label Hemoglobinuria paroxística nocturna (HPN) que se trata con eculizumab o ravulizumab según la etiqueta local, PNH is a rare, acquired life-threatening disease, characterized by presence of impaired red blood cells that are easily destroyed, leading to hemoglobin in the urine and anemia as main manifestations HPN es enfermedad rara, adqui q pone en peligro la vida, por la presencia de glóbu rojos deteriorados q se destruyen fácil, lo q lleva a la hemoglobina en orina y anemia como manifestaciones ppales, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2019-001619-21: OPTIMIZATION OF MAINTENANCE DOSE WITH ECULIZUMAB ACCORDING TO WEIGHT IN PATIENTS WITH ATYPIC HAEMOLITHIC URINE MUSCLE SYNDROME OPTIMIZACIÓN DE LA DOSIS DE MANTENIMIENTO CON ECULIZUMAB SEGÚN EL PESO EN PACIENTES CON SÍNDROME HEMOLÍTICO URÉMICO ATÍPICO

Not yet recruiting
4
10
Europe
Solution for infusion, SOLIRIS
HOSPITAL UNIVERSITARI DE BELLVITGE- IDIBELL, HOSPITAL UNIVERSITARI DE BELLVITGE-IDIBELL
ATYPICAL HEMOLYTIC UREMIC SYNDROME SÍNDROME HEMOLÍTICO URÉMICO ATÍPICO, ATYPICAL HEMOLYTIC UREMIC SYNDROME SÍNDROME HEMOLÍTICO URÉMICO ATÍPICO, Not possible to specify
 
 
2019-003440-74: Phase 4, Single-Arm Study of Ravulizumab in Adult Participants with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with High-Dose Eculizumab

Not yet recruiting
4
20
Europe
ULTOMIRIS, ALXN1210, Concentrate for solution for infusion, ULTOMIRIS
Alexion Pharmaceuticals Inc., Alexion Pharmaceuticals, Inc.
Paroxysmal nocturnal hemoglobinuria (PNH), Paroxysmal nocturnal hemoglobinuria (PNH), Diseases [C] - Blood and lymphatic diseases [C15]
 
 
BEST-NMOSD, NCT07010302: Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD

Not yet recruiting
4
160
Europe, US
Rituximab (R), Rituxan, Truxima, Eculizumab (Soliris®), Ravulizumab, Satralizumab, Inebilizumab
Massachusetts General Hospital, Patient-Centered Outcomes Research Institute, Charite University, Berlin, Germany, The Sumaira Foundation
NMOSD
02/29
02/30
NCT02946463 / 2016-002025-11: ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Checkmark In PNH
Apr 2018 - Apr 2018: In PNH
Completed
3
272
Europe, Canada, Japan, US, RoW
Ravulizumab, Eculizumab
Alexion Pharmaceuticals, Inc.
Paroxysmal Nocturnal Hemoglobinuria (PNH)
02/23
02/23
NCT06987864: An Extension Clinical Study of BCD-148 for the Treatment of Patients With PNH Previously Treated in Clinical Study No. BCD-148-2/NOCTURN

Completed
3
24
RoW
eculizumab
Biocad
Paroxysmal Nocturnal Hemoglobinuria (PNH)
11/22
11/22
NCT03748823 / 2017-002370-39: Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Completed
3
139
Europe, Canada, US, RoW
Ravulizumab OBDS, Ravulizumab, ALXN1210
Alexion Pharmaceuticals, Inc.
Paroxysmal Nocturnal Hemoglobinuria
02/21
08/23
2020-003565-19: Espacement personnalisé des perfusions d’eculizumab basé sur un suivi thérapeutique pharmacologique : évaluation médicoéconomique prospective multicentrique chez les patients en rémission atteints d’un syndrome hémolytique et urémique atypique nécessitant un traitement au long cours. Espacement personnalisé des perfusions d’eculizumab basé sur un suivi thérapeutique pharmacologique : évaluation médicoéconomique prospective multicentrique chez les patients en rémission atteints d’un syndrome hémolytique et urémique atypique nécessitant un traitement au long cours.

Not yet recruiting
3
80
Europe
SOLIRIS, L04AA25, Solution for injection, SOLIRIS
CHRU DE TOURS, CHRU DE TOURS
Patients en rémission atteints d’un syndrome hémolytique et urémique atypique nécessitant un traitement au long cours par eculizumab Patients en rémission atteints d’un syndrome hémolytique et urémique atypique nécessitant un traitement au long cours par eculizumab, Patients en rémission atteints d’un syndrome hémolytique et urémique atypique nécessitant un traitement au long cours par eculizumab Patients en rémission atteints d’un syndrome hémolytique et urémique atypique nécessitant un traitement au long cours par eculizumab, Not possible to specify
 
 
ECU-MG-303, NCT03759366 / 2016-001384-37: A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

Completed
3
12
Japan, US
Eculizumab
Alexion Pharmaceuticals, Inc.
Myasthenia Gravis, Myasthenia Gravis, Juvenile Form, Myasthenia Gravis, Generalized
01/22
11/23
ALPHA, NCT04469465 / 2019-003829-18: Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)

Completed
3
86
Europe, Canada, Japan, US, RoW
Danicopan, ALXN2040, Placebo, C5 Inhibitor
Alexion Pharmaceuticals, Inc.
Paroxysmal Nocturnal Hemoglobinuria
06/22
01/24
EspacECU, NCT04859608: Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring

Completed
3
40
Europe
Spacing of Eculizumab infusions
University Hospital, Tours, Centre Hospitalier Universitaire, Amiens, University Hospital, Angers, Centre Hospitalier Universitaire de Besancon, University Hospital, Caen, Centre Hospitalier of Chartres, Nantes University Hospital, University of Nancy, Poitiers University Hospital, Rennes University Hospital, University Hospital, Rouen, University Hospital, Strasbourg, France, Centre Hospitalier Universitaire de Nice, Hôpital Necker-Enfants Malades, Tenon Hospital, Paris, University Hospital, Lille, Reims University hospital, University Hospital, Clermont-Ferrand, Assistance Publique Hopitaux De Marseille, Hospices Civils de Lyon
Hemolytic-Uremic Syndrome, Atypical
06/22
12/23
APPLY-PNH, NCT04558918 / 2019-004665-40: Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

Hourglass Jun 2025 - Jun 2025 : 2-yrs safety and efficacy data for PNH
Completed
3
97
Europe, Japan, US, RoW
LNP023, iptacopan, Eculizumab, Ravulizumab
Novartis Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria (PNH)
09/22
03/23
COMMODORE 2, NCT04434092 / 2019-004931-21: A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors

Active, not recruiting
3
204
Europe, Japan, RoW
Crovalimab, Eculizumab
Hoffmann-La Roche, Chugai Pharmaceutical
Paroxysmal Nocturnal Hemoglobinuria
11/22
09/27

Ongoing
3
66
Europe
ECULIZUMAB, Concentrate for solution for infusion, Soliris 300 mg solution à diluer pour perfusion
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (AP-HP), DGOS
Adult patients with aHUS associated with HE and severe kidney involvement (needing dialysis or serum creatinine ≥ 354µM)., ND, Diseases [C] - Cardiovascular Diseases [C14]
 
 
ACCESS 2, NCT05131204 / 2020-002761-33: Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

Terminated
3
3
US
Cemdisiran, ALN-CC5, Eculizumab, Soliris, Pozelimab, REGN3918, Ravulizumab, ALXN1210, Ultomiris
Regeneron Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria
07/23
07/23
ConfIdeS, NCT04935177: Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx

Active, not recruiting
3
64
US
Imlifidase, IdeS, HMED-IdeS, PLEX, Plasma exchange, PE, IVIg, Intravenous immunoglobulin, Anti-CD20 antibodies, Rituximab, Eculizumab, Soliris, Remain on wait list
Hansa Biopharma AB
Kidney Transplantation in Highly Sensitized Patients
06/25
06/25
NCT06932744: Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

Recruiting
3
66
RoW
MY008211A tablets, Eculizumab Injection
Wuhan Createrna Science and Technology Co., Ltd
Paroxysmal Nocturnal Haemoglobinuria (PNH)
12/25
12/25
HRS-5965-301, NCT06593938: A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

Active, not recruiting
3
76
RoW
HRS-5965 capsule, Eculizumab Injection
Chengdu Suncadia Medicine Co., Ltd.
Paroxysmal Nocturnal Hemoglobinuria
12/25
12/25
ECU-MG-304, NCT06764160: Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG

Active, not recruiting
3
15
RoW
Eculizumab
Alexion Pharmaceuticals, Inc.
Generalized Myasthenia Gravis (gMG), Refractory gMG
01/26
01/26
ECU-NMO-304, NCT06724809: Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD

Recruiting
3
21
RoW
eculizumab
Alexion Pharmaceuticals, Inc., AstraZeneca
NMOSD, Neuromyelitis Optica Spectrum Disorders
04/27
04/27
HSK39297-301, NCT06799546: A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy

Recruiting
3
66
RoW
HSK39297 tablets, Eculizumab Injection
Haisco Pharmaceutical Group Co., Ltd.
PNH
12/25
12/25
Soliris, NCT05886244: Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China

Completed
3
25
RoW
Eculizumab
Alexion Pharmaceuticals, Inc., AstraZeneca
Paroxysmal Nocturnal Hemoglobinuria
04/25
04/25
GEMECULI, NCT05702996: Multicenter, Uncontrolled Pilot Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies

Not yet recruiting
3
10
Europe
Eculizumab administration
University Hospital, Rouen
Thrombotic Microangiopathies
09/25
09/25
NCT06449001: Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

Recruiting
3
6
Europe
Danicopan
Alexion Pharmaceuticals, Inc.
Paroxysmal Nocturnal Hemoglobinuria, PNH, Extravascular Hemolysis
07/27
07/28
Soliris, NCT05876351: Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China

Completed
3
25
RoW
Eculizumab
Alexion Pharmaceuticals, Inc., AstraZeneca
Atypical Hemolytic Uremic
05/25
05/25
HYPERSHU, NCT05726916: Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome

Recruiting
3
66
Europe
Soliris®, Eculizumab, Renin angiotensin system blockers
Assistance Publique - Hôpitaux de Paris
Hypertensive Emergency-associated Hemolytic Uremic Syndrome
05/26
11/27
ACCESS-1, NCT05133531 / 2020-004486-40: A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment

Recruiting
3
190
Europe, Canada, Japan, US, RoW
Ravulizumab, ALXN1210, Ultomiris, Pozelimab, REGN3918, Cemdisiran, ALN-CC5, Eculizumab, Soliris
Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Inc.
Paroxysmal Nocturnal Hemoglobinuria
01/27
01/27
COMMODORE 1, NCT04432584 / 2020-000597-26: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors

Active, not recruiting
3
190
Europe, Canada, Japan, US, RoW
Crovalimab, Eculizumab
Hoffmann-La Roche, Chugai Pharmaceutical
Paroxysmal Nocturnal Hemoglobinuria
09/27
09/27
2019-001829-26: A Trial to Evaluate the Safety and Activity of Eculizumab in PediatricPatients with Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD) Ensayo para evaluar la seguridad y actividad de eculizumab en pacientes pediátricos con trastorno del espectro de la neuromielitis óptica recidivante

Not yet recruiting
2/3
15
Europe
Soliris, Soliris, Concentrate for solution for infusion, Soliris
Alexion Pharmaceuticals Inc., ALEXION PHARMACEUTICALS INCORPORATED, Alexion Pharmaceuticals Inc, Alexion Pharmaceuticals Inc.
Neuromyelitis Optica Spectrum Disorder (NMOSD) Trastorno del espectro de la neuromielitis óptica (TENMO), Neuromyelitis Optica Spectrum Disorder (NMOSD) Trastorno del espectro de la neuromielitis óptica (TENMO), Diseases [C] - Nervous System Diseases [C10]
 
 
ECU-NMO-303, NCT04155424 / 2019-001829-26: A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

Terminated
2/3
5
Europe, Canada, Japan, US, RoW
Eculizumab, Soliris
Alexion Pharmaceuticals, Inc., Alexion Pharmaceuticals Inc, Alexion Pharmaceuticals Inc.
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
07/23
07/23
ACTRN12611000880943: Safety & Efficacy of Eculizumab to Prevent antibody mediated rejection in Living Donor Kidney Transplant Recipients Requiring Desensitization

Recruiting
2
80
 
Alexion Pharmaceuticals Australasia Pty Ltd, Alexion Pharmaceuticals Australasia Pty Ltd
Kidney transplant
 
 
ACTRN12611000461998: Study to evaluate if eculizumab is efficient and safe enough to be used for treatment of children with atypical hemolytic-uremic syndrome

Active, not recruiting
2
15
 
Alexion Pharmaceuticals Australasia Pty Ltd, Alexion Pharmaceuticals Australasia Pty Ltd
Atypical Hemolytic-Uremic Syndrome
 
 
ACTRN12612000333819: Safety and Efficacy of Eculizumab to prevent antibody mediated rejection in sensitized kidney transplant recipients from a deceased donor

Recruiting
2
40
 
Alexion Pharmaceuticals Inc, Alexion Pharmaceuticals Inc
kidney transplant
 
 
2017-003916-37: Stopping Eculizumab Treatment Safely in atypical Haemolytic Uraemic Syndrome (SETS aHUS)

Not yet recruiting
2
50
Europe
Solaris, Infusion, Solaris
Newcastle Upon Tyne Hospitals NHS Foundation Trust, National Institute for Health Research
Atypical Haemolytic Uraemic Syndrome (aHUS), aHUS is a rare disease caused by a fault in the complement system. The complement system is part of your body’s immune response that attacks bugs., Diseases [C] - Immune System Diseases [C20]
 
 
2017-004307-51: Inflammation inhibitors to reduce brain injury after a hemorrhagic stroke. Ontstekingsremmers om schade na bloeding tussen hersenvliezen te verminderen.

Ongoing
2
40
Europe
Powder for infusion, Soliris
University Medical Center Utrecht, ZonMW/Hersenstichting, Alexion Pharmaceuticals
Aneurysmal subarachnoid hemorrhage Aneurysmatische subarachnoïdale bloeding, Stroke Hersenvliesbloeding, Diseases [C] - Cardiovascular Diseases [C14]
 
 
2018-004382-13: Safety and efficacy of Cemdisiran in athypical hemolytic uremic syndrome Sicurezza ed efficacia di Cendisiran nella Sindrome emolitico-uremica atipica.

Not yet recruiting
2
12
Europe
ALN-CC5, [ALN-62643], Solution for injection
IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI, Alnylam Pharmaceutical Inc. Cambridge, MA, Istituto di Ricerche Farmacologiche Mario negri
Atypical Hemolytic Uremic Syndrome Sindrome emolitico uremica atipica, Atypical Hemolytic Uremic Syndrome Sindrome emolitico uremica atipica, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2020-003168-22: Study evaluating the efficacy of eculizumab in the treatment of gemcitabine-induced thrombotic microangiopathies. Etude évaluant l’efficacité de l’eculizumab dans le traitement des microangiopathies thrombotiques induites par la gemcitabine

Not yet recruiting
2
10
Europe
SOLIRIS®, EU/1/07/393/001, Solution for infusion, SOLIRIS®
Rouen University Hospital, Rouen University Hospital
Thrombotic microangiopathies induced by gemcitabine Microangiopathies thrombotiques induites par la gemcitabine, Thrombotic microangiopathies induced by gemcitabine Microangiopathies thrombotiques induites par la gemcitabine, Diseases [C] - Cancer [C04]
 
 
NCT04888507: Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy

Completed
2
6
Europe
Pozelimab, REGN3918, Cemdisiran, ALN-CC5
Regeneron Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria
05/22
05/23
REDEEM-1, NCT05116774 / 2020-004438-39: BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy

Terminated
2
12
Europe
Eculizumab, Soliris, Ravulizumab, Ultomiris, ALXN1210, ravulizumab-cwvz, BCX9930
BioCryst Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria (PNH)
09/23
09/23
NCT06513338: Complement C5 mAb in the Treatment of Anti-GBM Disease

Completed
2
8
RoW
Eculizumab
Peking University First Hospital
Autoimmune Diseases
12/24
12/24
NCT04702568 / 2020-000501-93: A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Terminated
2
19
Europe, RoW
BCX9930, Eculizumab, Ravulizumab
BioCryst Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria, PNH
10/23
10/23
EASE-NMO, NCT06673394: Eculizumab for Acute Attack of Neuromyelitis Optica Spectrum Disorder

Not yet recruiting
2
75
NA
Complement protein C5 inhibitor, eculizumab, IVMP, methylprednisolone, prednisolone
Tianjin Medical University General Hospital
Neuromyelitis Optica Spectrum Disorder Attack
12/25
12/25
ChiCTR2400084781: A Study on the Efficacy and Safety of Sequential Efgartigimod and Telitacicept Therapy in the Treatment of Generalized Myasthenia Gravis

Not yet recruiting
2
30
 
The patients in the treatment group received a dose of 10mg/kg of eculizumab via intravenous infusion over 1 hour once a week for 4 consecutive weeks in the first month. Starting from the second month, they began receiving a subcutaneous injection of 240mg of Telitacicept acetate weekly, and continued long-term Telitacicept acetate treatment until the end of the 24-week study observation period.
Peking University People's Hospital; Peking University People's Hospital, The research was funded by the National Natural Science Foundation of China (Grant No. 81303013).
myasthenia gravis
 
 
NCT05646563: Study of NM8074 in Adult PNH Patients with Inadequate Response to Soliris

Not yet recruiting
2
12
NA
NM8074, Soliris, Eculizumab
NovelMed Therapeutics
Paroxysmal Nocturnal Hemoglobinuria
05/27
01/28
NCT05731050: Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Not yet recruiting
2
6
NA
NM8074
NovelMed Therapeutics
PNH - Paroxysmal Nocturnal Hemoglobinuria
09/27
03/28
NCT06453135: Eculizumab for Prevention of Antibody-Mediated Rejection in ABO-Incompatible Living Donor Kidney Transplantation

Not yet recruiting
1/2
30
RoW
Eculizumab, Soliris
Tao Lin
Kidney Transplantation
07/25
12/25
NCT04103489: The Use of Eculizumab in HELLP Syndrome

Completed
1
3
US
Eculizumab, Soliris
Johns Hopkins University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
HELLP Syndrome (HELLP), Third Trimester, Complement Abnormality, Morbidity;Newborn, Maternal Injury, Preeclampsia Severe
08/23
09/23
NCT05863442: Comparative PK, Safety, Tolerability, Immunogenicity, and PD Profile Study of TUR03 and Soliris in Healthy Participants

Recruiting
1
120
RoW
Soliris 300 MG in 30 ML Injection, TUR03 300 MG in 30 ML Injection
Turgut Ardika PTY LTD
Healthy
07/24
10/24
SOLID-C19, NCT04288713: Eculizumab (Soliris) in Covid-19 Infected Patients

Available
N/A
NA
Eculizumab
Hudson Medical
Coronavirus
 
 
NCT04355494: SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19

No Longer Available
N/A
Europe, US
eculizumab, Soliris
Alexion Pharmaceuticals
COVID-19, Pneumonia, Viral, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
 
 
NCT04802083: COVID-19 Soliris Expanded Access Protocol

No Longer Available
N/A
NA
Eculizumab, Soliris, monoclonal antibody
Alexion Pharmaceuticals
Covid19
 
 
NAP, NCT04671810: Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria®

Completed
N/A
44
RoW
Elizaria®, Eculizumab
AO GENERIUM
Paroxysmal Nocturnal Hemoglobinuria
12/22
05/23
NCT05982938: Danicopan Early Access Program

Available
N/A
NA
Danicopan, ALXN2040
Alexion Pharmaceuticals, Inc.
Paroxysmal Nocturnal Hemoglobinuria, PNH, Extravascular Hemolysis
 
 
NCT06888622: BLAZE-Limiting Approach in NMOSD

Completed
N/A
9
RoW
Eculizumab administration
Huashan Hospital
Neuromyelitis Optica Spectrum Disorders (NMOSD)
03/25
03/25
SolirisPMS, NCT06448715: Real-World Treatment Study of Soliris (Eculizumab)

Completed
N/A
11
RoW
AstraZeneca
Observational
01/25
01/25
m-TMA, NCT06098378: Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With Eculizumab

Recruiting
N/A
30
Europe
University Hospital, Strasbourg, France
Thrombotic Microangiopathies
06/25
06/25
ChiCTR2300067949: The real world study of Eculizumab for paroxysmal nocturnal hemoglobinuria treatment in China

Not yet recruiting
N/A
10
 
Eculizumab
West China Hospitai, Sichuan University; West China Hospitai, Sichuan University, Apply for hospital project funds
paroxysmal nocturnal hemoglobinuria
 
 
ChiCTR2500098555: Study on the Safety and Efficacy of Eculizumab in Different Subgroups of Adults with Refractory Myasthenia Gravis

Recruiting
N/A
60
 
None; None
Shijiazhuang People s Hospital; Shijiazhuang People s Hospita, Hebei Provincial Myasthenia Gravis Center and key laboratory of Myasthenia gravis research.
Myasthenia gravis
 
 
eftansomatropin alfa (GX-H9) / Genexine
NCT04633057: A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency

Completed
3
168
RoW
TJ101, NordiFlex
TJ Biopharma Co., Ltd.
Pediatric Growth Hormone Deficiency
07/23
07/23
ersodetug (RZ358) / Rezolute
sunRIZE, NCT06208215: RZ358 Treatment for Congenital Hyperinsulinism

Recruiting
3
56
Europe, Canada, US, RoW
RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC, RZ358 (10 mg/kg) or Placebo + SOC, RZ358 (5-10 mg/kg) + SOC
Rezolute
Congenital Hyperinsulinism
04/25
09/26
NCT06881992: A Phase 3 Study of Ersodetug in Patients With Tumor-Associated Hyperinsulinism

Recruiting
3
48
US
Ersodetug, Placebo
Rezolute
Tumor- Associated Hyperinsulinism
09/27
09/27
RZ402 / Rezolute
NCT05712720: Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)

Active, not recruiting
2
100
US
Experimental: Group 1 - 50mg RZ402, Experimental: Group 2 - 200mg RZ402, Experimental: Group 3 - 400mg RZ402, Placebo: Group 4 - Placebo
Rezolute
Diabetic Macular Edema
05/24
05/25
tovecimig (CTX-009) / ABL Bio, Compass Therap
COMPANION-002, NCT05506943: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers

Active, not recruiting
2/3
150
US
CTX-009, Paclitaxel
Compass Therapeutics
Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
07/25
12/25
COMPANION-003, NCT05513742: A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer

Completed
2
49
US
CTX-009
Compass Therapeutics
Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
04/25
05/25
NCT04492033: A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients

Terminated
1/2
41
RoW
CTX-009 (ABL001), Paclitaxel, Irinotecan
Handok Inc., Compass Therapeutics, ABL Bio, Inc.
P1b: Advanced Solid Tumors, P2: Biliary Tract Cancer
01/24
01/25
NCT06548412: CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

Recruiting
1/2
50
US
Gemcitabine, Cisplatin, Durvalumab, CTX-009
M.D. Anderson Cancer Center, Compass Therapeutics, Inc
Metastatic Biliary Tract Cancer
05/27
05/29
NCT05167448: A Study of ES104 in Patients With Metastatic Colorectal Cancer

Active, not recruiting
1/2
58
RoW
ES104
Elpiscience (Suzhou) Biopharma, Ltd.
Metastatic Colorectal Cancer
05/26
07/26
ragistomig (ABL503) / ABL Bio, I-Mab
ABL503-1001, NCT04762641: This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors

Recruiting
1
100
US, RoW
ABL503
ABL Bio, Inc.
Advanced Solid Tumor
11/25
06/26
ABL501 / ABL Bio
NCT05101109: Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

Completed
1
24
RoW
ABL501, Bispecific antibody for LAG-3 and PD-L1
ABL Bio, Inc.
Advanced Solid Tumor
05/24
05/24
ABL103 / ABL Bio
ABL103-1001, NCT06126666: A Study with ABL103 in Subjects with Advanced or Metastatic Solid Tumors

Recruiting
1
96
RoW
ABL103
ABL Bio, Inc.
Advanced Solid Tumor
06/25
11/27
SBP-101 / SPARK BioPharma
NCT06747923: SB17170 Phase 2 Trial in IPF Patients

Recruiting
2
30
RoW
SB17170, Placebo
SPARK Biopharma
IPF, Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
04/26
10/26
NCT05795192: SB17170 Phase1 Trial in Healthy Volunteer

Completed
1
64
RoW
SB17170, Placebo
SPARK Biopharma
Safety Issues, Tolerability, Pharmacokinetics, Pharmacodynamics
02/24
03/24
NCT05522868: SB17170 Phase 1 Clinical Trial in Solid Tumors

Active, not recruiting
1
50
RoW
SB17170
SPARK Biopharma
Solid Tumor
05/25
06/25
NCT06846684: A Open-label, Drug-Drug Interaction With SB_MDZ in Healty Adult Subjects

Active, not recruiting
1
12
RoW
SB17170, SB_MDZ
SPARK Biopharma
Drug Drug Interaction (DDI)
06/25
06/25

Download Options